Real-World tagrisso study shows promise for lung cancer patients
NCT ID NCT03918304
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how well the drug Tagrisso (osimertinib) works and how safe it is for people with a certain type of lung cancer (non-small cell lung cancer with EGFR mutations) in everyday medical practice. Over 900 patients in Korea were observed while taking Tagrisso as their only treatment. The goal was to track side effects and see how long the drug kept the cancer from growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tagrisso (osimertinib)
What this could lead to
If successful, this study could confirm that Tagrisso works well and is safe for a broad range of patients with EGFR-mutant lung cancer in everyday clinical practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects like skin rash or diarrhea are possible, and the drug may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Busan, South Korea
-
Research Site
Chungcheongbuk-do, South Korea
-
Research Site
Daegu, South Korea
-
Research Site
Daejeon, South Korea
-
Research Site
Gangwon State, South Korea
-
Research Site
Gyeonggi-do, South Korea
-
Research Site
Incheon, South Korea
-
Research Site
Jeollabuk-do, South Korea
-
Research Site
Jeollanam-do, South Korea
-
Research Site
Seoul, South Korea